Article Details
Retrieved on: 2019-02-06 15:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>LUND, Sweden, Feb. 7, 2019 /PRNewswire/ -- Hansa Biopharma AB, the leader in immunomodulatory enzyme technology for rare IgG-mediated ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here